Confronting the Global Health Challenge of Hepatitis C

Janice Wahl, MD, executive director of Infectious Diseases at Merck Research Laboratories, discusses ongoing work to treat multiple genotypes of hepatitis C.
PUBLISHED WEDNESDAY, JANUARY 13, 2016
Janice Wahl, MD, executive director of Infectious Diseases at Merck Research Laboratories, discusses ongoing work to treat multiple genotypes of hepatitis C.



 
Recommended Articles
Study finds a common assortment of reasons for non-initiation of HCV therapy, regardless of patient race or ethnicity.
Managing the risk of hepatitis C and liver disease among infants born to mothers with chronic HCV is a challenge.
HCV patients with cirrhosis and severe sepsis face elevated risk of organ failure.
Anti-retroviral drug therapy may effectively treat hepatitis C-HIV coinfection.
$auto_registration$